Effect of abomasal glucose infusion on splanchnic and whole-body glucose metabolism in periparturient dairy cows

Six periparturient Holstein cows fitted with ruminal cannulas and permanent indwelling catheters in the hepatic portal vein, hepatic vein, mesenteric vein, and an artery were used to study the effects of abomasal glucose infusion on splanchnic and whole-body glucose metabolism. The experimental design was a split plot, with cow as the whole plot, treatment as the whole-plot factor, and days in milk (DIM) as the subplot factor. Cows were assigned to 1 of 2 treatments: the control (no infusion) or infusion (1,500 g/d of glucose infused into the abomasum from the day of calving). Cows were sampled at 12 d prepartum and at 4, 15, and 29 DIM. To study portal-drained visceral uptake of arterial glucose, [U-¹³C]glucose was continuously infused into the jugular vein on sampling days. Postpartum, voluntary dry matter intake and milk yield increased at a lower rate with the infusion compared with the control. The net portal flux of glucose increased with the infusion compared with the control, and 67 ± 5% of the infused glucose was recovered as increased portal flux of glucose. The net hepatic flux of glucose was lower with the infusion compared with the control; however, the net hepatic flux of glucose per kilogram of dry matter intake was not affected by treatment. The arterial concentrations of glucose and insulin decreased and concentrations of nonesterified fatty acids increased from prepartum to 4 DIM with the control, but these effects were not observed with the infusion. The arterial concentration of β-hydroxybutyrate decreased more from prepartum to 4 DIM with the infusion, compared with the control. Uptake of arterial [U-¹³C]glucose in the portal-drained viscera was affected neither by the infusion nor by the DIM and averaged 2.5 ± 0.2%. The whole-body glucose supply changed to be less dependent on the recycling of lactate (Cori cycle) with the infusion. It was concluded that small intestinal glucose absorption is an efficient source of glucose to the peripheral tissues of dairy cows in very early lactation. At least 67% of the available glucose was recovered in the portal vein without affecting hepatic gluconeogenesis. Infused cows produced less milk and had a lower feed intake, indicating that an improved glucogenic status in very early lactation impaired metabolic adaptations to lactation.     

Effects of rumen-protected choline and monensin on milk production and metabolism of periparturient dairy cows

Choline and monensin may be supplemented during the transition period with the objectives of aiding in fat metabolism and improving energy balance, respectively. The objectives of this study were to determine the effects of supplementing rumen-protected choline (RPC) and monensin in a controlled-release capsule (CRC) on metabolism, dry matter intake, milk production, and liver function in transition dairy cattle. Three weeks before expected calving, 182 Holsteins were randomly assigned to receive one of the following: a monensin CRC, 56 g/d of RPC until 28 d in milk, CRC + RPC, or neither supplement (control). Blood samples were collected at enrollment, 1 wk before calving, and in the first and second weeks after calving. Liver biopsies were obtained from multiparous cows randomly selected from each treatment group within 24 h and again 3 wk postpartum. Daily milk production was recorded through 60 d in milk. There were no interactions of the effects of RPC and CRC on any of the outcomes measured. Overall, cows that received RPC produced 1.2 kg/d more milk in the first 60 d of lactation, but this effect was attributable to an increase in milk production of 4.4 kg/d among cows with a body condition score ≥4 at 3 wk before calving; fat cows that received RPC ate 1.1 kg of DM/d more from wk 3 before calving through wk 4 after calving. Monensin supplementation significantly increased serum concentrations of glucose and urea, lowered concentrations of β-hydroxybutyric acid and aspartate aminotransferase in the peripartum period, and increased liver glycogen content at 3 wk into lactation. The metabolic effects of CRC are consistent with previous studies, and the effects on liver are novel. The mechanism by which RPC increased milk production was not revealed in this study and merits further research.     

Effects of prepartum diets varying in dietary energy density and monensin on early-lactation performance in dairy cows

Our objectives were to evaluate the effects of prepartum monensin supplementation and dry-period nutritional strategy on the postpartum productive performance of cows fed monensin during lactation. A total of 102 Holstein cows were enrolled in the experiment (32 primiparous and 70 multiparous). The study was a completely randomized design, with randomization restricted to balance for parity, body condition score, and expected calving date. A 2 × 2 factorial arrangement of prepartum treatments was used; the variables of interest were prepartum feeding strategy [controlled-energy diet throughout the dry period (CE) vs. controlled-energy diet from dry-off to 22 d before expected parturition, followed by a moderate-energy close-up diet from d 21 before expected parturition through parturition (CU)] and prepartum monensin supplementation [0 g/t (control, CON) or 24.2 g/t (MON); Rumensin; Elanco Animal Health, Greenfield, IN]. Lactation diets before and after the dry period contained monensin at 15.4 g/t. During the close-up period, cows fed CU had greater DM and NE_L intakes than cows fed CE. Calf BW at birth tended to be greater for cows fed CU than for those fed CE but was not affected by MON supplementation. Diet did not affect calving difficulty score, but cows supplemented with MON had an increased calving difficulty score. We found a tendency for a MON × parity interaction for colostral IgG concentration, such that multiparous MON cows tended to have lower IgG concentration than CON cows, but colostral IgG concentration for primiparous MON and CON cows did not differ. Postpartum milk yield did not differ between diets but tended to be greater for cows supplemented with MON. Milk fat and lactose content were greater for cows fed CU than for those fed CE, and lactose content and yield were increased for cows supplemented with MON. Solids-corrected and fat-corrected milk yields were increased by MON supplementation, but were not affected by diet. Overall means for postpartum DMI did not differ by diet or MON supplementation. The CU diet decreased the concentration of nonesterified fatty acids during the close-up period but increased it postpartum. Neither diet nor monensin affected β-hydroxybutyrate or liver composition. Overall, postpartum productive performance differed little between prepartum dietary strategies, but cows fed MON had greater energy-corrected milk production. In herds fed monensin during lactation, monensin should also be fed during the dry period.     

Effects of addition of essential oils and monensin premix on digestion, ruminal fermentation, milk production, and milk composition in dairy cows

Four ruminally cannulated, lactating Holstein cows were used in a 4 × 4 Latin square design (28-d periods) with a 2 × 2 factorial arrangement of treatments to study the effects of dietary addition of essential oils (0 vs. 2 g/d; EO) and monensin (0 vs. 350 mg/d; MO) on digestion, ruminal fermentation characteristics, milk production, and milk composition. Intake of dry matter averaged 22.7 kg/d and was not significantly affected by dietary additives. Apparent digestibilities of dry matter, organic matter, neutral detergent fiber, and starch were similar among treatments. Apparent digestibility of acid detergent fiber was increased when diets were supplemented with EO (48.9 vs. 46.0%). Apparent digestibility of crude protein was higher for cows fed MO compared with those fed no MO (65.0 vs. 63.6%). Nitrogen retention was not changed by additive treatments and averaged 27.1 g/d across treatments. Ruminal pH was increased with the addition of EO (6.50 vs. 6.39). Ruminal ammonia nitrogen (NH₃-N) concentration was lower with MO-supplemented diets compared with diets without MO (12.7 vs. 14.3 mg/100 mL). No effect of EO and MO was observed on total volatile fatty acid concentrations and molar proportions of individual volatile fatty acids. Protozoa counts were not affected by EO and MO addition. Production of milk and 4% fat-corrected milk was similar among treatments (33.6 and 33.4 kg/d, respectively). Milk fat content was lower for cows fed MO than for cows fed diets without MO (3.8 vs. 4.1%). The reduced milk fat concentration in cows fed MO was associated with a higher level of trans-10 18:1, a potent inhibitor of milk fat synthesis. Milk urea nitrogen concentration was increased by MO supplementation, but this effect was not apparent when MO was fed in combination with EO (interaction EO × MO). Results from this study suggest that feeding EO (2 g/d) and MO (350 mg/d) to lactating dairy cows had limited effects on digestion, ruminal fermentation characteristics, milk production, and milk composition.     

Effects of prepartum administration of a monensin controlled release capsule on rumen pH, feed intake, and milk production of transition dairy cows

Effects of prepartum administration of a monensin controlled release capsule (CRC) on rumen pH, dry matter intake, and milk production during the transition period and early lactation were determined in 16 multiparous Holstein cows. Cows were divided into blocks of 2 depending on calving date. Cows were fed either a close-up dry cow or a lactating cow total mixed ration ad libitum. Rumen pH was monitored continuously using indwelling probes. Monensin did not affect average daily rumen pH, time below pH 6, time below pH 5.6, area below pH 6, and area below pH 5.6 throughout the experiment. Average daily pH, time below pH 6, and time below pH 5.6 before calving were 6.62, 65.6 min/d, and 17.6 min/d, respectively, and did not differ among the weeks before calving. Average daily pH, time below pH 6, and time below pH 5.6 were 6.19, 443.3 min/d, and 115.5 min/d, respectively, during the first week after calving, and were 6.36, 204.3 min/d, and 52.4 min/d, respectively, during the sixth week after calving. In the weeks after calving, average daily pH showed a quadratic increase, time below pH 6 showed a quadratic decrease, and time below pH 5.6 showed a linear decrease. Monensin did not affect dry matter intake and daily yields of milk, milk fat, and milk protein. Results suggest that prepartum administration of a monensin CRC did not increase rumen pH in multiparous cows fed the experimental diets during the transition period and early lactation.     

Effect of a monensin controlled release capsule on metabolic parameters in transition dairy cows

A prospective field study involving 251 Holstein cows and heifers from five dairy farms near Guelph, Ontario, Canada, was conducted to measure the effect of monensin delivered in a controlled release capsule 3 wk precalving on metabolic function in dairy cows immediately pre- and postcalving. At 3 wk before expected calving, cows were randomly assigned to receive either a controlled release capsule containing monensin or to serve as negative controls. Cows were blood sampled once per week precalving and once in the week following calving, at the same time of day and the same day of the week. Serum was evaluated for beta-hydroxybutyrate (BHBA), nonesterified fatty acids (NEFA), cholesterol, urea, glucose, calcium, and phosphorus. Monensin-treated cows had significantly decreased NEFA and BHBA and significantly increased concentrations of serum cholesterol and urea in the week immediately precalving. No effect of treatment was observed for calcium, phosphorus, or glucose in the precalving period. After calving, concentrations of phosphorus were lower and BHBA tended to be lower, and cholesterol and urea were higher in monensin-treated cows. There was no effect of treatment on NEFA, glucose, or calcium in the first week postcalving. Monensin treatment administered precalving significantly improved indicators of energy balance in both the immediate precalving and postcalving periods. The findings indicate better energy metabolism in monensin-treated cows as they approach calving. Improvement of energy balance before calving is important for the prevention of energy associated metabolic diseases, such as retained placenta, clinical ketosis, and displaced abomasum, which might occur immediately postcalving.     

Effect of a monensin controlled-release capsule on rumen and blood metabolites in Florida Holstein transition cows

The objective of this study was to determine the effect of a monensin controlled-release capsule administered intraruminally at dry-off on rumen volatile fatty acids, NH3, lactate, pH, and energy blood metabolites in transition dairy cows fed Florida typical diets. In March 2003, 24 cows (10 primiparous and 14 multiparous) dried-off 50 to 70 d before expected parturition were randomly assigned to a treatment (n=12, oral capsule of monensin) or a control group (n=12, no capsule). Both groups received the same diet and were exposed to the same environment and management conditions. At assignment, at 21 d before expected parturition, at calving, and at 7, 14, and 21 d postpartum, blood samples were taken and body condition scores were determined. At 10 d postpartum, rumen and blood samples were obtained in the morning before the first feeding and at 2, 4, and 6 h after feeding. Serum nonesterified fatty acids (NEFA), beta-hydroxybutyrate (BHBA), and glucose were measured. Rumen samples were analyzed for concentrations of acetic, propionic, butyric, L- and D-lactic acids, and NH3. Data for rumen and blood metabolites were analyzed by ANOVA, mixed models for repeated measures. Volatile fatty acids were not different between groups. Multiparous treated cows had a significant reduction in rumen NH3 at 6 h after feeding. Treatment with monensin significantly increased body condition score at calving in multiparous cows. During the postpartum period, NEFA and BHBA were noticeably lower in treated than in control primiparous cows. This difference was not observed in multiparous cows.     

Long-term effects of feeding monensin on methane production in lactating dairy cows

The objective of this study was to determine the long-term effects of feeding monensin on methane (CH₄) production in lactating dairy cows. Twenty-four lactating Holstein dairy cows (1.46 ± 0.17 parity; 620 ± 5.9 kg of live weight; 92.5 ± 2.62 d in milk) housed in a tie-stall facility were used in the study. The study was conducted as paired comparisons in a completely randomized design with repeated measurements in a color-coded, double-blind experiment. The cows were paired by parity and days in milk and allocated to 1 of 2 treatments: 1) the regular milking cow total mixed ration (TMR) with a forage-to-concentrate ratio of 60:40 (control TMR; placebo premix) vs. a medicated TMR (monensin TMR; regular TMR + 24 mg of Rumensin Premix/kg of dry matter) fed ad libitum. The animals were fed and milked twice daily (feeding at 0830 and 1300 h; milking at 0500 and 1500 h) and CH₄ production was measured prior to introducing the treatments and monthly thereafter for 6 mo using an open-circuit indirect calorimetry system. Monensin reduced CH₄ production by 7% (expressed as grams per day) and by 9% (expressed as grams per kilogram of body weight), which were sustained for 6 mo (mean, 458.7 vs. 428.7 ± 7.75 g/d and 0.738 vs. 0.675 ± 0.0141, control vs. monensin, respectively). Monensin reduced milk fat percentage by 9% (3.90 vs. 3.53 ± 0.098%, control vs. monensin, respectively) and reduced milk protein by 4% (3.37 vs. 3.23 ± 0.031%, control vs. monensin, respectively). Monensin did not affect the dry matter intake or milk yield of the cows. These results suggest that medicating a 60:40 forage-to-concentrate TMR with 24 mg of Rumensin Premix/kg of dry matter is a viable strategy for reducing CH₄ production in lactating Holstein dairy cows.     

Milk performance and glucose metabolism in dairy cows fed rumen-protected fat during mid lactation

Feeding rumen-protected fat (RPF) can improve energy supply for dairy cows but it affects glucose metabolism. Glucose availability is a precondition for high milk production in dairy cows. Therefore, this study investigated endocrine regulation of glucose homeostasis and hepatic gene expression related to glucose production because of RPF feeding in lactating cows. Eighteen Holstein dairy cows during second lactation were fed either a diet containing RPF (mainly C16:0 and C18:1; FD; n = 9) or a control diet based on corn starch (SD; n = 9) for 4 wk starting at 98 d in milk (DIM). Feed intake and milk yield were measured daily and milk composition once a week. Blood samples were taken weekly for analyses of plasma triglyceride, nonesterified fatty acids (NEFA), β-hydroxybutyrate, bilirubin, urea, lactate, glucose, insulin, and glucagon. At 124 DIM, an intravenous glucose tolerance test (GTT; 1 g/kg of BW^0.75) was performed after a 12-h period without food. Blood samples were taken before and 7, 14, 21, and 28 min after glucose administration, and plasma concentrations of glucose, insulin, and glucagon were measured. Glucose half-life as well as areas under the concentration curve for glucose, insulin, and glucagon were calculated. After slaughter at d 28 of treatment, liver samples were taken to measure mRNA abundance of pyruvate carboxylase, cytosolic phosphoenolpyruvate carboxykinase, glucose 6-phosphatase (G6Pase), and facilitative glucose transporter 2. Dry matter intake, but not energy and protein intake, was lower in FD than in SD. Milk yield during lactation decreased more in SD than in FD, and milk protein was lower in FD than in SD. Plasma concentrations of triglycerides and NEFA were higher in FD than in SD. Plasma insulin concentrations were lower and the glucagon:insulin ratios were higher in FD than in SD. Fasting glucose concentration before GTT was lower, and fasting glucagon concentrations tended to be higher in FD than in SD. In liver, fat content tended to be higher and G6Pase mRNA abundance was lower in FD than in SD. Lower hepatic G6Pase mRNA abundance was associated with reduced fasting plasma glucose concentrations, but the glucose-induced insulin response was not affected by RPF feeding. Hepatic G6Pase gene expression might be affected by DMI and might be involved in the regulation of glucose homeostasis in dairy cows, resulting in a lower hepatic glucose output after RPF feeding.     

Effects of glucose, propionic acid, and nonessential amino acids on glucose metabolism and milk yield in Holstein dairy cows

Whole-body glucose rate of appearance (Ra) responses and milk lactose secretion were compared in dairy cows receiving duodenal infusions of glucose (Glc), a mixture of 5 nonessential amino acids (NEAAm), or ruminal infusions of propionic acid (C3). Four mid-lactation Holstein cows, fitted with both duodenum and rumen cannulas, were used in a 4 × 4 Latin square design with 14-d periods. Cows were fed a grass silage-based diet (Ctrl) that provided 88% of net energy of lactation and 122% of protein requirements. Concentrate was formulated with wheat (21.5%) and barley (20%) containing some starch. Isoenergetic infusions (5.15 Mcal/d of digestible energy) of Glc into the duodenum (7.7 mol/d), C3 into the rumen (14.1 mol/d), or NEAAm into the duodenum (in mol/d; Ala: 1.60; Asp: 0.60; Glu: 5.94; Gly: 1.22; Ser: 2.45) were given as a supplement to the Ctrl diet. During each period on d 13, [6,6-²H₂]glucose was infused into one jugular vein and blood samples were taken from the other jugular vein to measure glucose enrichment and determine Ra. Dry matter intake decreased slightly with the infusions (6%), but did not differ among them. Whole body glucose Ra averaged 502, 745, 600, and 576 mmol/h for Ctrl, Glc, C3, and NEAAm, respectively. It increased with the increase in energy supply (Ctrl vs. infusions) and differed according to the nutrients infused. The Ra response was higher with Glc and C3 than with NEAAm and higher with Glc than with C3. Plasma concentrations of insulin were not affected, but insulin-like growth factor 1 increased with infusions. Plasma glucagon increased with NEAAm, which could favor the increased Ra. Overall, milk lactose yield (137, 141, 142, and 130 mmol/h for Ctrl, Glc, C3, and NEAAm, respectively) was not modified by the infusions, but was lower with NEAAm compared with Glc and C3. Changes in lactose yield did not parallel the increase in Ra, and therefore the ratio of lactose yield to Ra decreased with the infusions and was lower in Glc compared with C3, suggesting a shift of glucose utilization away from lactose synthesis toward other pathways, including mammary metabolism. Intestinal Glc was the most efficient nutrient in terms of increasing glucose Ra; however, there was no direct link between the increases in whole body glucose Ra observed with the 3 types of nutrients and milk lactose yield.     

Effects of dietary alpha-amylase on metabolism and performance of transition dairy cows

Twenty-four multiparous Holstein cows [body weight, 759 kg (SD = 30 kg); body condition score, 3.2 (SD = 0.13)] were used in a randomized complete block design to determine the effect of feeding α-amylase during the transition period on rumen fermentation, key metabolic indicators, and lactation performance. Cows were assigned to either a control diet or the control diet supplemented with α-amylase (662 fungal amylase units per gram, AMA) at 0.1% of diet dry matter (DM). Experimental diets were fed from 21 d before expected calving through 21 d in milk. From 22 to 70 d in milk, all cows were fed a similar lactation cow diet. Average pre- and postpartum DM intakes were 12.4 and 17.8 kg/d, respectively, and did not differ between treatments; however, DM intakes during the last week prepartum decreased to a greater degree in AMA than control cows compared with wk −2. Supplementing diets with α-amylase tended to increase proportions of ruminal butyrate prepartum but not postpartum. Treatment differences were not detected for concentrations of insulin in plasma and lipid and glycogen in liver tissue. Prepartum, concentrations of β-hydroxybutyrate and nonesterified fatty acids were increased in cows fed AMA compared with the control diet. Postpartum, concentrations of glucose in plasma tended to be increased by feeding AMA. Increased plasma β-hydroxybutyrate and nonesterified fatty acids pre- but not postpartum and a tendency for increased plasma glucose postpartum demonstrate shifting reliance from lipid- to carbohydrate-based metabolism postpartum in cows fed α-amylase.     

Prepartum monensin for the reduction of energy associated disease in postpartum dairy cows

A total of 1317 Holstein cows from 45 farms in the Canadian provinces of Quebec, Prince Edward Island (PEI) and Ontario were enrolled in a randomized trial during 1998 and 1999 to further confirm the efficacy of a monensin controlled release capsule in preventing periparturient disease in lactating dairy cows. Cows were randomized on the farms to receive either a monensin controlled release capsule (CRC) 2 to 4 wk before expected calving or to serve as negative controls. Health data were collected for 90 d postcalving and were analyzed with logistic regression accounting for the intraherd correlation with generalized estimating equations. Monensin CRC significantly reduced the incidence of both clinical ketosis and abomasal displacement post-calving. There was a numerical but nonsignificant decrease in the incidence of retained placenta in cows receiving a monensin CRC. A pooled analysis of two separate but similar studies (conducted in 1995 and 1998) demonstrated a strengthened association between monensin CRC administration precalving and reduced periparturient disease. A 40% reduction in both abomasal displacement and clinical ketosis was observed with precalving administration of a monensin CRC. In addition, the larger dataset highlighted a trend for a 25% reduction in the incidence of retained placenta in monensin-treated cows. Improved energy metabolism as a result of monensin treatment is likely the mechanism for the reduction in incidence of all three of these diseases. Thus the term "energy associated disease" was created to assess the combined impact of the precalving monensin treatment on the incidence of retained placenta, displaced abomasum, and clinical ketosis. The monensin controlled release capsule reduced the incidence of energy associated disease by 30%.     

Effects of a monensin controlled-release capsule or premix on attenuation of subacute ruminal acidosis in dairy cows

The effects of monensin, administered either as a controlled release capsule (CRC) or a premix, on attenuating grain-induced subacute ruminal acidosis (SARA) and on ruminal fermentation characteristics in Holstein cows receiving a total mixed ration were investigated in two experiments. In both experiments, six multiparous, rumen-fistulated Holstein cows were used in a two-treatment, two-period crossover design with 6-wk periods. In Experiment 1, treatments were either a monensin CRC or a placebo CRC. In Experiment 2, treatments were either a monensin premix or a placebo premix. In both experiments, at the beginning of wk 4 SARA was induced in experimental cows for a 10-d period with a grain challenge model, and ruminal pH was measured continuously using indwelling pH probes. The administration of monensin either as a CRC or a premix had no effect on ruminal pH characteristics. Neither monensin CRC nor premix had an effect on ruminal volatile fatty acid concentrations, but reduced the acetate:propionate ratio. Monensin premix-treated cows were observed to have increased milk yield, largely as a result of a higher dry matter intake in monensin-treated cows compared to control cows. Milk fat content and yield were lower in monensin-treated cows compared to placebo-treated cows during SARA. In conclusion, there is no evidence that monensin was efficacious in raising ruminal pH during SARA under the conditions employed in this study.     

Effects of prepartum 2,4-thiazolidinedione on metabolism and performance in transition dairy cows

Thiazolidinediones (TZD) are potent synthetic ligands for peroxisome proliferator-activated receptor-γ that have been shown previously to reduce plasma nonesterified fatty acids and increase peripartal dry matter intake (DMI) in dairy cows. Data from Holstein cows (n = 36) entering their second or greater lactation were used to determine whether late prepartum administration of TZD would affect periparturient metabolism, milk production, and ovarian activity. Cows were administered 0, 2.0, or 4.0 mg of TZD/kg of BW by intrajugular infusion once daily from 21 d before expected parturition until parturition. Plasma samples were collected daily from 22 d before expected parturition through 21 d postpartum and twice weekly from wk 4 through 9 postpartum. In response to increasing TZD dosage, plasma nonesterified fatty acid concentrations decreased linearly during the postpartum period (d 0 to +21: 348, 331, 268 ± 31 μEq/L, respectively). Plasma concentrations of glucose were highest in cows administered 4.0 mg of TZD/kg of BW during the peripartum and postpartum periods (d −7 to +7: 57.9, 57.8, 61.1 ± 0.8 mg/dL and d 0 to +21: 51.6, 49.3, 54.7 ± 1.1 mg/dL, respectively). Plasma concentrations of β-hydroxybutyrate were increased during the peripartum period by TZD administration (9.6, 9.9, 10.2 ± 0.3 mg/dL) but were not affected during the postpartum period. Plasma insulin was not affected by treatment during any time period. Postpartum liver triglyceride content was decreased linearly (11.0, 10.4, 4.2 ± 1.6%) and glycogen content was increased linearly (2.16, 2.38, 2.79 ± 0.19%) by prepartum TZD administration. Prepartum TZD administration linearly increased DMI during the peripartum period (d −7 to +7: 16.1, 17.2, 17.3 ± 0.5 kg/d). Cows administered TZD prepartum maintained higher postpartum body condition scores than control cows (wk 1 through 9: 2.77, 2.89, 3.02 ± 0.05). There was no effect of prepartum TZD on milk yield; however, yields of 3.5% fat-corrected milk (52.2, 54.6, 48.0 ± 1.6 kg/d) and most other milk components were decreased in cows that received 4.0 mg of TZD/kg of BW prepartum. Prepartum TZD administration linearly decreased the number of days to first ovulation (29.3, 28.3, 19.0 ± 3.6 d). These results suggest that prepartum administration of TZD improves metabolic health and DMI of periparturient dairy cows and may decrease reliance on body fat reserves during early lactation.     

Long-term effects of feeding monensin on milk fatty acid composition in lactating dairy cows

The objective of this study was to determine the long-term effects of feeding monensin on milk fatty acid (FA) profile in lactating dairy cows. Twenty-four lactating Holstein dairy cows (1.46 ± 0.17 parity; 620 ± 5.9 kg of live weight; 92.5 ± 2.62 d in milk) housed in a tie-stall facility were used in the study. The study was conducted as paired comparisons in a completely randomized block design with repeated measurements in a color-coded, double blind experiment. The cows were paired by parity and days in milk and allocated to 1 of 2 treatments: 1) the regular milking cow total mixed ration (TMR) with a forage-to-concentrate ratio of 60:40 (control TMR; placebo premix) vs. a medicated TMR [monensin TMR; regular TMR + 24 mg of Rumensin Premix per kg of dry matter (DM)] fed ad libitum. The animals were fed and milked twice daily (feeding at 0830 and 1300 h; milking at 0500 and 1500 h). Milk samples were collected before the introduction of treatments and monthly thereafter for 6 mo and analyzed for FA composition. Monensin reduced the percentage of the short-and medium-chain saturated FA 7:0, 9:0, 15:0, and 16:0 in milk fat by 26, 35, 19, and 6%, respectively, compared with the control group. Monensin increased the percentage of the long-chain saturated FA in milk fat by 9%, total monounsaturated FA by 5%, total n-6 polyunsaturated FA (PUFA) by 19%, total n-3 PUFA by 16%, total cis-18:1 by 7%, and total conjugated linoleic acid (CLA) by 43% compared with the control group. Monensin increased the percentage of docosahexaenoic acid (22:6n-3), docosapentaenoic acid (22:5n-3), and cis-9, trans-11 CLA in milk fat by 19, 13, and 43%, respectively, compared with the control. These results suggest that monensin was at least partly effective in inhibiting the biohydrogenation of unsaturated FA in the rumen and consequently increased the percentage of n-6 and n-3 PUFA and CLA in milk, thus enhancing the nutritional properties of milk with regard to human health.     

Whole-body glucose metabolism and mammary energetic nutrient metabolism in lactating dairy cows receiving digestive infusions of casein and propionic acid

This study analyzed the effect of propionate (C3) and casein (CN) on whole-body and mammary metabolism of energetic nutrients. Three multiparous Holstein cows fitted with both duodenal and ruminal cannulas were used in 2 replicated Youden squares with 14-d periods. Effects of CN (743 g/d in the duodenum) and C3 (1,042 g/d in the rumen) infusions, either separately or in combination as supplements to a grass silage diet, were tested in a factorial arrangement. The control diet provided 97% of energy and protein requirements. Within each period, blood samples were taken (d 11) from the carotid artery and the right mammary vein to determine net uptake of energetic nutrients. Plasma blood flow was calculated using the Fick principle (based on Phe and Tyr). On d 13, [6,6-²H₂]glucose was infused in the jugular vein to determine whole-body glucose rate of appearance (Ra) based on enrichments in arterial plasma. Both C3 and CN treatments increased whole-body Ra (17% and 13%, respectively) but only CN increased milk (18%) and lactose (14%) yields, suggesting no direct link between whole-body Ra and milk yield. When CN was infused alone, the apparent ratio of conversion of CN carbon into glucose carbon was 0.31 but, when allowance was made for the CN required to support the extra milk protein output, the ratio increased to 0.40, closer to the theoretical ratio (0.48). This may relate to the observed increases in arterial glucagon concentrations for CN alone. Conversely, the apparent conversion of infused C3 carbon alone to glucose was low (0.31). With C3, mammary plasma flow increased as did uptakes of lactate, Ala, and Glu whereas the uptake for β-hydroxybutyrate (BHBA) decreased. Mammary net carbon balance suggested an increase with C3 treatment in glucose, lactate, Ala, and Glu oxidation within the mammary gland. Mammary glucose uptake did not increase with CN treatment, despite an increase in glucose arteriovenous difference and extraction rate, because plasma flow decreased (−17%). Whereas CN, alone or in combination with C3, increased both lactose and protein yields, only mammary AA (and BHBA in CN alone) uptake increased because plasma flow decreased (−17%). These data suggest that the observed variations of milk lactose yield (and other milk components) are linked to metabolic interchanges between several energetic nutrients at both the whole-body and mammary levels and are not explained by increases in whole-body glucose availability.     

Effects of lasalocid or monensin supplementation on digestion, ruminal fermentation, blood metabolites, and milk production of lactating dairy cows

Six ruminally fistulated midlactating multiparous Holstein cows were used in a double 3 × 3 Latin square design (35-d periods) to study the effects of lasalocid (LAS) and monensin (MON) supplemented at 24 mg/kg of dry matter on digestion, ruminal fermentation, blood metabolites, and milk production. Cows were blocked according to milk production and fed a red clover silage-based total mixed ration (17.8% crude protein) without supplementation or supplemented with LAS or MON. Daily dry matter intake, milk production, and milk fat and protein concentrations were similar among treatments and averaged 23.5 kg, 36.6 kg, 3.36%, and 3.38%, respectively. Rumen lipogenic:glucogenic volatile fatty acids and NH₃-N concentration were lower, and apparent digestibility of dry matter, organic matter, crude protein, and gross energy were higher with than without ionophore supplementation. Compared with LAS, MON increased concentrations of plasma urea-N and milk urea-N, and excretion of urinary urea-N and total N. Monensin also decreased N retention and tended to reduce plasma concentration of nonessential AA in comparison with LAS. Both ionophores reduced daily fecal excretion of N by 13 g compared with the control, but MON increased daily losses of urinary N by 36 g compared with LAS. Results from this study suggest that postabsorptive metabolism of N might be altered by the type of ionophore fed.     

Short communication: Effects of a monensin premix on milk fatty acid content during subacute ruminal acidosis in dairy cows

The effects of a monensin premix on milk fatty acid content during grain-induced subacute ruminal acidosis (SARA) in Holstein cows receiving a total mixed ration was investigated. Six multiparous, rumen-fistulated Holstein cows were used in a two-treatment, two-period crossover design with 6-wk periods. Experimental treatments were either a monensin premix or a placebo premix. At the beginning of wk 4, SARA was induced in experimental cows for a 10-d period using a grain challenge model. The administration of a monensin premix elevated milk fat proportion of total short-chain saturated fatty acids (sum of C4 to C15). Milk fat proportions of conjugated linoleic acid isomers were unaffected. Linolenic acid (C18:3n3) proportion in milk fat of monensin-treated cows were lower when compared with placebo-treated cows during the SARA period. Results from this study indicate that dietary supplementation with monensin during SARA had little effect on milk fatty acid content.     

Effects of monensin on ruminal forage degradability and total tract diet digestibility in lactating dairy cows during grain-induced subacute ruminal acidosis

The effects of monensin premix supplementation on ruminal pH characteristics and forage degradability, and total tract diet digestibility during grain-induced subacute ruminal acidosis (SARA) in lactating dairy cows receiving a total mixed ration were investigated. Six multiparous, rumen-fistulated Holstein cows were used in a 2-treatment, 2-period (5 wk per period) crossover design. During wk 5 (d 29 to 35) of each period, SARA was induced using a grain challenge model, and ruminal pH was measured continuously using indwelling pH probes. Ruminal degradation of corn silage and alfalfa haylage was determined using the in situ (nylon bag) technique, and total tract diet digestibility was determined by total fecal collection during wk 5. Monensin supplementation did not affect dry matter intake, milk yield, and composition, and ruminal pH characteristics under these experimentally induced SARA conditions. Rates of ruminal forage fiber degradability were similar between control and monensin-treated cows; however, monensin supplementation increased total tract fiber digestion. This study indicates that monensin altered total tract nutrient digestion by increasing fiber digestion at postruminal sites.     

Effects of monensin and dietary soybean oil on milk fat percentage and milk fatty acid profile in lactating dairy cows

The objective of this study was to investigate the effect of monensin (MN) and dietary soybean oil (SBO) on milk fat percentage and milk fatty acid (FA) profile. The study was conducted as a randomized complete block design with a 2 × 3 factorial treatment arrangement using 72 lactating multiparous Holstein dairy cows (138 ± 24 d in milk). Treatments were [dry matter (DM) basis] as follows: 1) control total mixed ration (TMR, no MN) with no supplemental SBO; 2) MN-treated TMR (22 g of MN/kg of DM) with no supplemental SBO; 3) control TMR including 1.7% SBO; 4) MN-treated TMR including 1.7% SBO; 5) control TMR including 3.4% SBO; and 6) MN-treated TMR including 3.4% SBO. The TMR (% of DM; corn silage, 31.6%; haylage, 21.2%; hay, 4.2%; high-moisture corn, 18.8%; soy hulls, 3.3%; and protein supplement, 20.9%) was offered ad libitum. The experiment consisted of a 2-wk baseline, a 3-wk adaptation, and a 2-wk collection period. Monensin, SBO, and their interaction linearly reduced milk fat percentage. Cows receiving SBO with no added MN (treatments 3 and 5) had 4.5 and 14.2% decreases in milk fat percentage, respectively. Cows receiving SBO with added MN (treatments 4 and 6) had 16.5 and 35.1% decreases in milk fat percentage, respectively. However, the interaction effect of MN and SBO on fat yield was not significant. Monensin reduced milk fat yield by 6.6%. Soybean oil linearly reduced milk fat yield and protein percentage and linearly increased milk yield and milk protein yield. Monensin and SBO reduced 4% fat-corrected milk and had no effect on DM intake. Monensin interacted with SBO to linearly increase milk fat concentration (g/100 g of FA) of total trans-18:1 in milk fat including trans-6 to 8, trans-9, trans-10, trans-11, trans-12 18:1 and the concentration of total conjugated linoleic acid isomers including cis-9, trans-11 18:2; trans-9, cis-11 18:2; and trans-10, cis-12 18:2. Also, the interaction increased milk concentration of polyunsaturated fatty acids. Monensin and SBO linearly reduced, with no significant interaction, milk concentration (g/100 g of FA) of short- and medium-chain fatty acids (<C16). Soybean oil reduced total saturated FA and increased total monounsaturated FA. These results suggest that monensin reduces milk fat percentage and this effect is accentuated when SBO is added to the ration.